AdBio partners

Our Ventures team supports the launch of startups based on University of Michigan technologies and research discoveries. We provide a full suite of resources, services and funding to help you launch sustainable, impactful world changing startups. The Ventures team will engage with you from day one to establish clear and executable commercialization, business formation and funding strategies. As your startup project begins to take form we can provide grant funding and investment capital, as well as business know-how, talent resources and connections to a nationwide network of investors. Whether it is helping you find the perfect team member, investment partner or connecting you with service providers, we have you covered.

Our expertise in biopharma and biotech investments. With decades of experience and a robust network within the biopharma and biotech industries, our team offers unparalleled insight into the scientific and financial landscapes. We are dedicated to identifying transformative therapies and supporting companies that are pioneering the future of healthcare. Empowering entrepeneurs to build leading companies Biovance Capital works closely with entrepreneurs to build leading companies with transformative treatments for patients in need. Stage: We invest in early-stage companies at seed and Series A rounds across Europe, with a focus in Southern countries. Technology: We invest in biotech companies developing therapeutics in any modality and therapeutic area. We require robust and appropriate preclinical models and patented or patentable assets before investing. Market: Large target market with a clear regulatory pathway for approval, with favorable reimbursement and pricing policies. Exit Potential: Sectors with VC/M&A or IPO activity, featuring profitable exits and multiple potential acquirers. Sustainability: During the due diligence process, sustainability risks are taken into account, and whenever identified, mitigation measures are proposed.

We are a venture capital firm specialised in seed investment for innovative early stage companies. BGV generally acts as lead investor. Our team is made up of life science experts and business analysts that can guide life science companies’ development throughout the entire research and development process. BioGeneration Ventures leverages its knowledge gained from working with a diverse network. This includes universities, early stage biotech companies and large pharma. We enable a range of sector-relevant expertise to build and accelerate product development and transform entrepreneurs and their companies to become attractive investment opportunities within the life sciences industry. Our Strategy BioGeneration Ventures (BGV) was launched in 2006. We manage over EUR 250 million across four funds. BGV invests in medical and healthcare innovations that have high potential to positively impact patients. BGV works with an ethos founded in sound novel science. We seek those innovations that have a truly differentiated scientific basis, supported by convincing experimental data. These innovations must be compelling and stand out in the global scientific arena. Only innovations that can address a significant unmet medical need are considered for investment. We aspire to invest in solutions that provide substantial healthcare impact. Progressing a project from discovery to clinical proof-of-concept requires a breadth of experience that founding teams usually do not have from the outset. Through our extensive network and experience we help founders build their companies to extend their capabilities. We guide our portfolio companies along their journey from the scientific discovery to a targeted product development track. Together with the founders, we seeks to shape the companies and define the objectives that enable a successful exit. Our partnerships BGV invests in partnerships with other professional investors in life sciences and has built relationships with various academic institutions (such as Leiden University), venture capital investors in the Netherlands, the EU and the US. Forbion: BGV operates a joint venture partnership with Forbion, a leading European life sciences venture capital fund. Mibiton: Mibiton provides loans to enable promising young life sciences companies to purchase equipment. BGV actively supports the investment activities with BGV Managing Partner Edward van Wezel serving as a member of the board. Our Investors: BGV has a broad investor base comprising private equity/wealth managers, pension funds, academic institutions, regional development funds and private investors.

We invest in opportunities backed by deep science. Xora is an early-stage investment platform of Temasek. We typically invest as a lead or co-lead investor in the Seed and Series A rounds, and later rounds (via our parent company). While we are not limited by geography, we prioritize opportunities that possess a strong linkage with the Singapore science & technology ecosystem. Leveraging the Temasek global network of investors and operating companies, we are active partners to ambitious founders building the next generation of impactful, world-changing companies. Our Team Our team possesses strong technical domain expertise in both physical and life sciences, and the intersection thereof, and are steeped in the nuances of early-stage deep science investing and venture building. We are global citizens with business experience in major markets. Our principles guide our engagement process and our investment decisions.We start with the people on the journey and a shared vision of the future. ​ We look for dogged persistence, unbounded creativity, acute self-awareness, a sense of urgency, and a passion for impact. We embrace both the technical and people complexity of science-based opportunities. ​ We welcome early and frequent contact and appreciate the opportunity to inform an emerging narrative. ​ We prefer brainstorming to pitches, and relationships to transactions. ​ We commit more than capital; we pledge our mindshare and our network.

Investing in groundbreaking technologies means actively shaping the future. Passion is what drives us. Look deeper is our approach. About Onsight Ventures Think globally, act locally. We bring together bright minds to create technologies that have a global impact. Based in Innsbruck, Onsight Ventures is setting new momentum for high-tech start-ups in Austria and Europe. Supported by founding partners Hermann Hauser Investment, Round2 Capital, I.E.C.T., and Standortagentur Tirol, Onsight Ventures builds on a Europe-wide network of industry leading start-ups, universities and experts, to work closely with and support outstanding management teams in the implementation of their technology-based business ideas. Our vision – to work with tomorrow's most outstanding entrepreneurs today. Our goal – to support the development of young companies in reaching their goals and thus partake in actively shaping the future. Our core valuesAmbition: BioNTech, a company largely unknown before the COVID crisis, is making history. This has been achieved following the founding of a successful spin-off, led by three physicians - including Tyrolean Christoph Huber, a member of the Onsight advisory board. Excellence: We don't have to look to Silicon Valley or China for inspiration or knowledge; here in Europe we have excellent university and non-institute-based research.There is no lack of innovation. Convinced by their potential, our sweet spot is academic start-ups and university spin-offs. Impact: The 21st century is presenting us and our planet with major challenges. We are convinced that young entrepreneurs can achieve a positive impact with their technologies and business models by pursuing their goals with passion. Our responsibility as an investor is to help sustainable technologies grow both capital and know-how. Integrity: Entrepreneurship is a team sport. The road to building an internationally successful company is a rocky one. That's why trust, honesty and integrity play a crucial role in the long-term cooperation between founder teams and investors.

Since 2006 we’ve backed Yale faculty doing cutting edge research on some of the world’s largest problems. With Yale as our largest investor, we’ve supported teams developing much-needed therapeutics, advanced tools and materials for industry, and critical interventions for a warming planet. Our thesis is that great people and great science lead to great impact. YALE AND NEW HAVEN We are primarily interested in companies with a Yale connection, typically technology developed at and licensed from Yale. We also invest in companies located in the greater New Haven area, and, in exceptional cases, non-Yale/non-New Haven companies in which we have strong, personal connections to the founders or investors or where we can add substantial value. INVESTING IN PEOPLE In making investment decisions, we weigh the strength of the team as much as the technology or markets being addressed – often more. We look for creative thinking, high intelligence, passion, and a deep commitment to working hard for success. Building great businesses takes time and hard work. THERE AT THE START We are interested in investing as early as a good idea comes together, or later, as the team is formed and the business develops. We have been co-founders of a number of our portfolio companies, and find that the most rewarding (and hardest) thing we do. We typically make first investments of $500,000 to $1 million, and, if a company is tracking well, look to invest an additional $2 to $2.5 million over multiple financing rounds. We are happy to syndicate with other investors who share our views and approach to investing.